AstraZeneca adds to its treatments for blood cancer with $100M deal

AstraZeneca announced today (July 5) it has agreed to buy a company working on a cancer cure.

The company will hand over $100 million for TeneoTwo, Inc. in an upfront payment that will include its phase 1 clinical-stage CD19/CD3 T-cell engager, TNB-486, that is being evaluated in relapsed and refractory B-cell non-Hodgkin lymphoma.

With the deal, AstraZeneca is adding to its hematology pipeline, which already spans therapeutic modalities and mechanisms designed to address a wide-range of blood cancers.

New medicine

The company said by buying TNB-486, it hopes to accelerate the development of this potential new medicine for B-cell hematologic malignancies including the diffusion of large B-cell lymphoma and follicular lymphoma. It says this will help build on the success of its existing medicine Calquence (acalabrutinib) already being sold for the treatment of the disease.

TNB-486 belongs to a class of therapeutic antibodies known as T-cell engagers, which are emerging as a promising therapeutic approach in hematologic malignancies and solid tumors.

T-cell engagers are bispecific molecules that are engineered to redirect the immune system’s T-cells to recognize and kill cancer cells.

The post AstraZeneca adds to its treatments for blood cancer with $100M deal appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Source

About the Author: Biotech Today

You might like